drugset / Trial / NCT07674719

Remimazolam on the Incidence of Postoperative Acute Kidney Injury

NCT07674719

Not yet recruiting 78 enrolled Seoul National University Bundang Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

We hypothesized that in patients undergoing elective hepatobiliary-pancreatic surgery, the group in which anesthesia is induced and maintained with remimazolam during surgery would maintain hemodynamic stability and reduce the incidence of postoperative acute kidney injury compared to propofol. The purpose is to provide practical evidence for perioperative management differentiated from other surgeries for hepatobiliary-pancreatic surgery patients for whom intraoperative fluid therapy is restricted.

Timeline

Start
2026-06-26
Primary completion
2027-06-26
Completion
2028-06-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Propofol Small molecule 4 mg/ml
Comparator Propofol Small molecule 5 mg/ml
Subject Remimazolam Small molecule 0.3 ug/ml
Subject Remimazolam Small molecule 1.5 ug/ml

Indications